Several studies have shown a reduction in the risk of surgery associated with the concomitant increase in anti-tumor necrosis factor α (TNFα) drug prescription, thus inferring a positive impact of anti-TNFα therapy on IBD natural history. Here, TNF is linked to inflammatory bowel disease.